1.71  1.71 (100%)		02-10 16:00
Open: 1.71 High: 1.71 Volume: 648,213		Pre. Close: 1.71 Low: 1.71 Market Cap: 4(M)

Short term
Mid term
Targets	6-month :		1-year :
Resists	First :		Second :
Pivot price
Supports	First :		Second :
MAs	MA(5) :		MA(20) :
	MA(100) :		MA(250) :
MACD	MACD :		Signal :
%K %D	K(14,3) :		D(3) :
RSI	RSI(14):
52-week	High :		Low :

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Aptose Biosciences Inc. operates as a clinical-stage biopharmaceutical enterprise, dedicated to discovering and advancing personalized therapeutic solutions to address critical unmet medical needs within the field of oncology, primarily focusing on the United States market. Its active clinical pipeline features several promising candidates. APTO-253 is currently undergoing Phase 1a/b clinical evaluation for patients battling relapsed or treatment-resistant blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another compound, HM43239, is progressing through Phase 1/2 clinical trials, specifically targeting individuals with relapsed or refractory AML. Furthermore, luxeptinib is in Phase 1a/b clinical testing, designed to treat patients suffering from recurring or treatment-resistant B-cell malignancies—such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas—as well as AML and HR MDS. Aptose also has APL-581 under development, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. The company has established strategic agreements with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986, Aptose Biosciences Inc. previously operated as Lorus Therapeutics Inc. before adopting its current name in August 2014. Its corporate headquarters are located in Toronto, Canada.

Tue, 17 Jun 2025
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech

Fri, 02 May 2025
Aptose Biosciences Inc (NASDAQ: APTO) Share Price, APTO Stock News, APTO Share Price & Updates - Kalkine

Thu, 24 Apr 2025
Aptose Bioscienc (APTO) Stock Price, News & Analysis - Stock Titan

Fri, 28 Mar 2025
Aptose Biosciences Inc. SEC 10-K Report - TradingView

Thu, 23 Mar 2023
Aptose Reports Results for the Fourth Quarter and Full Year 2022 - GlobeNewswire

Wed, 29 Dec 2021
Aptose to Participate in Two Biotech Events in January 2022 - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	(%)
Held by Institutions	(%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin	%
Operating Margin	%
Return on Assets (ttm)	%
Return on Equity (ttm)	%
Qtrly Rev. Growth	%
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth	%
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow

Dividend
Forward Dividend
Dividend Yield	0%
Dividend Pay Date
Ex-Dividend Date